Adaptimmune Therapeutics plc, of Oxford, U.K., said it priced an underwritten public offering of 14.3 million of its American depositary shares (ADSs) at $4.20 each. The company also granted the underwriters a 30-day option to purchase up to an additional 2.145 million ADSs at the public offering price. The gross offering size is expected to be about $60.1 million with net proceeds to be used to advance the company's wholly owned pipeline of SPEAR T-cell candidates through clinical trials as well as other general corporate purposes. Citigroup, Cowen and Co. and Leerink Partners are acting as joint book-running managers for the offering. Guggenheim Securities is acting as lead manager.
Bioclin Therapeutics Inc., of San Ramon, Calif., said it closed a $30 million series B financing round led by new investors Sofinnova Ventures and Ysios Capital, and included existing investors Healthcap, Life Sciences Partners and Tekla Capital Management. The company is developing a first-in-class anti-FGFR3 (fibroblast growth factor receptor 3) monoclonal antibody and the proceeds will be used to advance the lead development candidate, B-701, to treat patients with metastatic bladder cancer, or metastatic urothelial carcinoma, who have relapsed or are refractory to platinum therapy.
Calithera Biosciences Inc., of South San Francisco, said it priced its previously announced underwritten public offering of 6.83 million shares of its common stock at $10.25 per share. Gross proceeds are expected to be approximately $70 million, which could grow if the underwriters exercise their 30-day option to purchase up to 1.02 million of additional shares of common stock at the public offering price. Leerink Partners is acting as sole book-running manager for the offering. Wells Fargo Securities is acting as a lead manager and JMP Securities is acting as a co-manager for the offering.
Imprimis Pharmaceuticals Inc., of San Diego, said it entered agreements with two accredited investors for a registered direct placement of 1.312 million shares of common stock at $2.40 each for aggregate gross proceeds of $3.148 million. National Securities Corp., a wholly owned subsidiary of National Holdings Inc., acted as the exclusive placement agent for the offering.
Innovus Pharmaceuticals Inc., of San Diego, said all remaining outstanding convertible notes have been redeemed and their current debt obligation has been reduced by approximately $1.3 million and also eliminated approximately $0.3 million in derivative liabilities.
Fight Against Cancer Innovation Trust (FACIT), of Toronto, said it has made a seed stage investment in Propellon Therapeutics, a start-up company created by FACIT and focused on developing a portfolio of WDR5-targeted anti-cancer therapeutics. The investment, combined with non-dilutive capital, achieved a targeted $3 million financing for the lead program's development. Propellon will now be able accelerate the nomination of a candidate drug and position for financing and/or entering a strategic partnership for clinical trials in patients with hematological cancers.
Regenxbio Inc., of Rockville, Md., said it has priced an underwritten public offering of 3.7 million shares of its common stock at $20.50 each with gross proceeds expected to be approximately $75.85 million. The company has granted the underwriters a 30-day option to purchase an additional 555,000 shares of common stock at the public offering price. Morgan Stanley, BofA Merrill Lynch and Piper Jaffray & Co. are acting as joint book-running managers. Chardan Capital Markets LLC is acting as co-manager of the offering.
Therapix Biosciences Ltd., of Tel Aviv, Israel, which is developing cannabinoid-based therapies, said it priced its IPO selling 2 million American depository shares (ADSs), each representing 40 ordinary shares of the company, at $6 each. The gross proceeds are expected to be $12 million. Therapix has granted the underwriters a 45-day option to purchase up to an additional 300,000 ADSs to cover overallotments, if any. The company plans to use the net proceeds from the offering to advance the formulation and clinical development efforts for its two lead product candidates, including phase II trials, and for working capital and other general corporate purposes. The company's ADSs will trade on the Nasdaq Capital Market under "TRPX."
Vect-Horus, of Marseille, France, which is focused on the design of vectors that facilitate the delivery of drugs into the brain and other organs, said it completed a new fundraising round generating €2.5 million (US$2.7 million), from private shareholders including Société de Capital Risque Provençale et Corse, a wholly owned subsidiary of Banque Populaire Méditerranée. By combining pharmaceutical agents to its vectors, the company enables their transport across the blood-brain barrier. Proof of concept of the technology in animal models has been demonstrated by developing different vectorized molecules, among them the endogenous neuropeptide neurotensin, which is in regulatory preclinical studies.
Vital Therapies Inc., of San Diego, which is developing Elad, a cell-based therapy targeting the treatment of acute forms of liver failure, said it priced an underwritten public offering of 8.75 million newly issued shares of its common stock at $4 per share for gross proceeds of approximately $35 million. The company has also granted the underwriters a 30-day option to purchase up to an additional 1.312 million shares of its common stock at the public offering price.